PortViewPortView
IBB logo

iShares Biotechnology (IBB) ETF Holdings & Analysis

ETFOther

$211.03+0.10%
1-year price historyRange $139.07 – $216.96
52-week range$211.03
$138.79$217.12

What IBB does

The iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.

Fund profile

Category
Other
AUM
$10.42B
Holdings
10
52-week high
$217.12
52-week low
$138.79

Top holdings

Top 1047%
HoldingWeight
AMGEN INC8.53%
VERTEX PHARMACEUTICALS8.04%
GILEAD SCIENCES7.20%
REGENERON PHARMACEUTICALS5.70%
ARGENX SE ADR3.78%
MODERNA3.57%
NATERA3.17%
REVOLUTION MEDICINES2.81%
ILLUMINA INC2.31%
BIOGEN2.27%

Sector allocation

Healthcare100.00%

Geographic allocation

United States86.20%
Netherlands4.19%
Switzerland2.39%
Denmark2.36%
United Kingdom1.67%
Canada0.70%
Ireland0.67%
Germany0.66%
France0.53%
China0.16%

PortView Portfolio Insights

PortView analyzes how IBB fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze IBB in PortView →

Related securities

Related stocks

Frequently asked questions

What does IBB track?
IBB is the iShares Biotechnology ETF, a Other ETF.
What is the expense ratio of IBB?
Expense ratio data for IBB is shown on the page when available from our data provider.
What are the largest holdings in IBB?
Top holdings include AMGN, VRTX, GILD, REGN, ARGX.
How can PortView analyze IBB overlap with other ETFs?
PortView computes the holdings overlap between IBB and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.